These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 1531213

  • 1. Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.
    Sebolt-Leopold JS, Vincent PW, Beningo KA, Elliott WL, Leopold WR, Heffner TG, Wiley JN, Stier MA, Suto MJ.
    Int J Radiat Oncol Biol Phys; 1992; 22(3):549-51. PubMed ID: 1531213
    [Abstract] [Full Text] [Related]

  • 2. Oncogenic transforming potential of nitroimidazole radiosensitizers.
    Hall EJ, Hei TK.
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
    [Abstract] [Full Text] [Related]

  • 3. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
    Cole S, Stratford IJ, Bowler J, Nolan J, Wright EG, Lorimore SA, Adams GE.
    Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
    [Abstract] [Full Text] [Related]

  • 4. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
    Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J.
    Int J Radiat Oncol Biol Phys; 1992 Jul; 22(3):545-8. PubMed ID: 1735694
    [Abstract] [Full Text] [Related]

  • 5. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
    Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC.
    Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
    [Abstract] [Full Text] [Related]

  • 6. In vitro assessment of the oncogenic potential of nitroimidazole radiosensitizers.
    Hei TK, Geard CR, Osmak RS, Hall EJ.
    Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1653-8. PubMed ID: 3839777
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Binger M, Workman P.
    Cancer Chemother Pharmacol; 1991 Sep; 29(1):37-47. PubMed ID: 1742848
    [Abstract] [Full Text] [Related]

  • 8. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).
    Campora E, Vidili G, Oliva C, Ardizzoni A, Rosso R.
    Oncology; 1991 Sep; 48(5):403-5. PubMed ID: 1836058
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
    Walton MI, Workman P.
    Cancer Chemother Pharmacol; 1988 Sep; 22(4):275-81. PubMed ID: 3168141
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.
    Walling J, Stratford IJ, Adams GE, Stephens MA.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Apr; 53(4):641-9. PubMed ID: 3258298
    [Abstract] [Full Text] [Related]

  • 13. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
    Kenward H, Elliott J, Lee T, Pelligand L.
    BMC Vet Res; 2017 Aug 16; 13(1):244. PubMed ID: 28814338
    [Abstract] [Full Text] [Related]

  • 14. Phase II trials of ondansetron with high-dose cisplatin.
    Kris MG.
    Semin Oncol; 1992 Aug 16; 19(4 Suppl 10):23-7. PubMed ID: 1387247
    [Abstract] [Full Text] [Related]

  • 15. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069.
    Workman P, Walton MI.
    Int J Radiat Oncol Biol Phys; 1984 Aug 16; 10(8):1307-10. PubMed ID: 6547936
    [Abstract] [Full Text] [Related]

  • 16. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
    Fitzpatrick LR, Lambert RM, Pendley CE, Martin GE, Bostwick JS, Gessner GW, Airey JE, Youssefyeh RD, Pendleton RG, Decktor DL.
    J Pharmacol Exp Ther; 1990 Aug 16; 254(2):450-5. PubMed ID: 2166791
    [Abstract] [Full Text] [Related]

  • 17. Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analogues.
    Walling JM, Stratford IJ, Adams GE, Silver AR, Ahmed I, Jenkins TC, Fielden EM.
    Int J Radiat Oncol Biol Phys; 1986 Jul 16; 12(7):1083-6. PubMed ID: 3755712
    [Abstract] [Full Text] [Related]

  • 18. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
    Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, Finn AL, Hesketh PJ.
    Semin Oncol; 1992 Aug 16; 19(4 Suppl 10):67-71. PubMed ID: 1387253
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
    Jeremić B.
    Srp Arh Celok Lek; 1996 Aug 16; 124(5-6):131-4. PubMed ID: 9102832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.